Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barker

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Journal of the American Academy of Dermatology|August 20, 2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis CouncilBruce Strober, Caitriona Ryan, Peter van de Kerkhof, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Dermatology and Therapy|May 3, 2025
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of LifeMatthias Augustin, Jonathan Barker, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 27, 2022
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trialUlrich Mrowietz, Jonathan Barker, Curdin Conrad, et al.
Ebiomedicine|June 26, 2024
Exploratory multi-omics analysis reveals host-microbe interactions associated with disease severity in psoriatic skinYing Yang, Peter Olah, Zoltan Radai, et al.
Journal of the American Academy of Dermatology|March 4, 2023
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 studyBoni E Elewski, Mark G Lebwohl, Milan J Anadkat, et al.
Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.
The Journal of Investigative Dermatology|October 4, 2016
Acne and Telomere Length: A New Spectrum between Senescence and Apoptosis PathwaysSimone Ribero, Marianna Sanna, Alessia Visconti, et al.
Infection and Immunity|July 25, 2018
The Psoriasis Risk Allele <i>HLA-C*06:02</i> Shows Evidence of Association with Chronic or Recurrent Streptococcal TonsillitisKarita Haapasalo, Lotta L E Koskinen, Jari Suvilehto, et al.
Trials|February 12, 2020
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trialSuzie Cro, Prakash Patel, Jonathan Barker, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Journal of the American Academy of Dermatology|August 20, 2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis CouncilBruce Strober, Caitriona Ryan, Peter van de Kerkhof, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Dermatology and Therapy|May 3, 2025
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of LifeMatthias Augustin, Jonathan Barker, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 27, 2022
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trialUlrich Mrowietz, Jonathan Barker, Curdin Conrad, et al.
Ebiomedicine|June 26, 2024
Exploratory multi-omics analysis reveals host-microbe interactions associated with disease severity in psoriatic skinYing Yang, Peter Olah, Zoltan Radai, et al.
Journal of the American Academy of Dermatology|March 4, 2023
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 studyBoni E Elewski, Mark G Lebwohl, Milan J Anadkat, et al.
Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.
The Journal of Investigative Dermatology|October 4, 2016
Acne and Telomere Length: A New Spectrum between Senescence and Apoptosis PathwaysSimone Ribero, Marianna Sanna, Alessia Visconti, et al.
Infection and Immunity|July 25, 2018
The Psoriasis Risk Allele <i>HLA-C*06:02</i> Shows Evidence of Association with Chronic or Recurrent Streptococcal TonsillitisKarita Haapasalo, Lotta L E Koskinen, Jari Suvilehto, et al.
Trials|February 12, 2020
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trialSuzie Cro, Prakash Patel, Jonathan Barker, et al.
Pageof 7